Kairos Pharma Ltd (KAPA) Quick Liquidity

KAPA (Kairos Pharma Inc) - company brandmark

Kairos Pharma Ltd (KAPA) generates revenue by bringing oncology treatments to market, specifically drugs targeting metastatic tumors. This chart of the asset's value with a coefficient of 12.55 reflects the dynamics of a business developing medications to combat therapy resistance in lung and prostate cancers. Due to its status as a leading innovator, Kairos Pharma Ltd (KAPA) maintains high shareholder loyalty and the trust of the medical community.

KAPA: kairospharma.com Intermediate Coverage Ratio 09/17/2024 - 10/31/2026

KAPA (Kairos Pharma Ltd): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Price kairospharma.com|KAPA - Average Forecast Price
- market capitalization details:
Market Value Kairos Pharma Inc|KAPA - Value Adjusted for Debt and Cash
- book capitalization data:
Accounting Value per Share Kairos Pharma|KAPA - Accounting Value of Company|Market Capitalization to Book Value Ratio kairospharma.com|KAPA - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Kairos Pharma Ltd|KAPA - Long-Term Debt to Capital|Short-Term Debt to Equity kairospharma.com|KAPA - Aggregate Debt Obligations|Debts to Book Capitalization Kairos Pharma Inc|KAPA - Long-Term Debt|Company Short-Term Debt Kairos Pharma|Quick Ratio kairospharma.com
- earnings and valuation multiples information:
KAPA - Net Profit
Summary company analytics:Kairos Pharma Limited - KAPA
Finished products of kairospharma.com

Maintaining a costly cold chain for the delivery of oncology drugs requires a high level of operational mobility from Kairos Pharma Ltd (KAPA). By analyzing the quick liquidity structure, the investor assesses the company's ability to instantaneously settle short-term debts using cash and accounts receivable, intentionally excluding illiquid drug inventories to identify real risks of cash flow gaps or excessive capital freezing.

Analysis of competing companies

ONC: Quick Ratio|Immediate Liquidity Halozyme Corp (HALO)|Quick Liquidity Revolution Medicines|AAPG: Intermediate Coverage Ratio|Quick Liquidity Indicator CGON (CG Oncology)|URGN (UroGen Pharma Ltd) - Intermediate Coverage Ratio|Quick Ratio BCAX (Bicara Bio)|PSNL - Quick Liquidity Indicator|ERAS: Quick Liquidity Indicator|DCTH - Quick Ratio|Y-mAbs Therapeutics, Inc. (YMAB) - Quick Liquidity|Aura Biosciences Inc - Intermediate Coverage Ratio|CADL (Candel Therapeutics Inc.) - Quick Ratio|Immediate Liquidity Accuray, Inc. ARAY|Quick Liquidity SELLAS Life Sciences (SLS)|Quick Ratio actuatetherapeutics.com (ACTU)|Quick Ratio CTOR (Citius Oncology)|Quick Ratio TuHURA Biosciences Inc. HURA|Protara - Quick Ratio|Interim Coverage Ratio Fate Pharma FATE|aadibio.com (WHWK) - Quick Liquidity|TScan Therapeutics, Inc. - Intermediate Coverage Ratio|Quick Liquidity Champions Oncology Inc|Immediate Liquidity XBiotech USA XBIT|Quick Liquidity CEL-SCI Corporation (CVM)|Interim Coverage Ratio OS Therapies, Inc.|Radiopharm Theranostics Limited - Quick Liquidity Indicator|Intermediate Coverage Ratio ARTV|ANL - Quick Liquidity|Critical Liquidity Ratio VERU|TPST: Quick Ratio|Xilio Therapeutics - Intermediate Coverage Ratio|RENB (Renovaro Biosciences) - Quick Ratio|Quick Ratio Mural Bio|Quick Liquidity OnKure Therapeutics Inc (OKUR)|GDTC (w2.cytomed.sg) - Intermediate Coverage Ratio|Quick Liquidity Curis CRIS|APLM - Quick Liquidity Indicator|Tharimmune, Inc. - Quick Ratio|ADVB - Quick Ratio|GNPX (Genprex) - Quick Liquidity Indicator|Calidi Biotherapeutics, Inc. - Intermediate Coverage Ratio|Quick Liquidity Sunshine Biopharma, Inc.|Quick Liquidity XBIO|Quick Liquidity Indicator SLRX (Salarius Pharmaceuticals)|Intermediate Liquidity Ratio PPBT|Quick Ratio AONC (American Oncology Network, Inc.)|BGNE: Immediate Liquidity Ratio|CKPT - Quick Liquidity|ELEV - Quick Ratio|ICAD: Quick Ratio|Ikena Oncology (IKNA) - Quick Ratio|Quick Liquidity Notable Labs|Viracta - Critical Liquidity Ratio|Quick Ratio MOR|Quick Ratio NAYA Biosciences Corp (NAYA)|Quick Ratio AAPGV (Ascentage Pharma Group)